Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06433193
Other study ID # DIALYSS-CLI-CIP02
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 22, 2024
Est. completion date April 24, 2024

Study information

Verified date May 2024
Source Nextkidney S.A.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary aim of this early feasibility clinical trial is to assess the biochemical safety of dialysate regeneration with the optimised PAK HDsorbent cartridge in a limited number (n=3) of participants and treatments (one therapy per subject). As a secondary aim, we will assessthe therapy efficacy of the PAK HD sorbent therapy in short-daily hemodialysis (SDHD) and compare it to that of conventional CHD underthe same therapy settings. Following up from the preceding FIH trial, this continuation aims at demonstrating that the optimised PAK HD sorbent system has overcome previous problems of increased dialysate acidity and provides improved control over the patient's acid-base balance.


Recruitment information / eligibility

Status Completed
Enrollment 3
Est. completion date April 24, 2024
Est. primary completion date April 24, 2024
Accepts healthy volunteers No
Gender All
Age group 21 Years to 79 Years
Eligibility Inclusion Criteria: 1. Subjects must be adults >/= 21 years old and <80 years old. 2. Subjects must be weighing >/= 55kg and <90kg (patient's dry weight). 3. Subjects must have stable haemoglobin >/= 10.5g/dL 2 months prior to enrolment 4. Subjects' pre-dialysis serum values must be within the following range, 2 months prior to enrolment: Patient allowable serum biochemistry ranges Allowable pre-dialysis serum values Na >/= 132 mmol/L or </= 145mmol/L HCO3 >/= 15mmol/L or </= 30mmol/L K >/= 3.5mmol/L or </= 5.8mmol/L 5. Subjects on stable on thrice weekly 4-h HD schedule. Stability is defined as: - Haemodynamic stability during dialysis (absence of hypotensive events and symptomatic arrhythmias), no angina pectoris, AND - No altered level of consciousness during dialysis. 6. Subjects with a well-functioning vascular access (native fistula graft): - capable of providing a blood flow rate of >/= 250 mL/min, AND - no vascular access revision and stable shunt flow for at least 4 weeks prior to enrolment. 7. Subjects capable of understanding the informed consent form and give informed consent. 8. Subjects willing and able to comply with study procedures and to attend all study follow-up visits. 9. Subjects who are female of reproducible age to practice birth control methods. 10. Subjects can be either gender. Exclusion Criteria: 1. Subjects with haemoglobin level of <10.5g/dL in any measurement 2 months prior to enrolment. 2. Subjects with the following pre-dialysis serum values in any measurement 2 months prior to enrolment: - sodium concentration <132 mmol/L or > 145mmol/L - bicarbonate <15mmol/L or >30mmol/L - plasma potassium concentration <3.5mmol/L or >5.8mmol/L - urea <15mmol/L or >28 mmol/L 3. Subjects with severe hypertension: systolic blood pressure > /=180 mmHg, diastolic blood pressure >/=120 mmHg in any officemeasurement less than 4 weeks prior to enrolment. 4. Subjects with chronic obstructive pulmonary disease or any respiratory disease that may predispose to CO2 retention. 5. Subjects with impaired liver function. Impaired liver function is defined as an elevated ALT (alanine aminotransferase) by 3-fold orgreater above the upper limit of normal. 6. Subjects with episodes of haemolysis in any measurement 3 months prior to enrolment. 7. Subjects with a central venous catheter. 8. Subjects with vascular access dysfunction (whether or not requiring an intervention), i.e. failure to achieve and/ or sustain a bloodflow of >/=250 mL/min and/or signs of compromised vascular access patency (according to the opinion of the investigator) within 4weeks prior to enrolment. 9. Subjects with vascular access related infection less than 4 weeks prior to enrolment 10. Subjects requiring an average ultrafiltration volume >2.8 L per 4-h treatment in mid-week dialysis session in the past 4 weeks priorto enrolment. 11. Subjects who are on heparin free dialysis 12. Subjects who are unable to provide informed consent. 13. Subjects who are unable to comply with study procedures. 14. Subjects with psychosocial problems which may negatively influence dialysis treatment. 15. Subjects who participated in another clinical intervention or device trial less than 12 weeks prior to enrolment, are currentlyparticipating or intend to participate in such a trial. 16. Subjects who are pregnant, breast feeding, or planning a pregnancy within the study period. 17. Subjects with a life expectancy <1 year. 18. Subjects who are anticipating a living donor kidney transplantation within < 2 months of the study period. 19. Subjects with recent history of drug and/or alcohol abuse in the last 3 months prior to enrolment.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
PAK HD Sorbent Therapy
Study Period 1: Subjects will receive their normal prescribed 4h CHD treatments Monday or Tuesday. On Wednesday or Thursday, one 4h CHD therapy will be performed at a dialysate flow rate (QD) of 300mL/min, identical to the dialysate flow rate of the PAK HD sorbent therapy. Blood and dialysate samples will be collected during treatment and sent for analysis, for comparison with PAK HD sorbent treatment. Study Period 2: Subjects will again receive their normal prescribed 4h CHD treatments Monday or Tuesday. On Wednesday or Thursday, a 2h PAK HD +/- 2h CHD therapy will be performed. Blood and dialysate samples will again be collected during treatment and sent for analysis, for comparison with the CHD therapy of the first period. After completion of study period 2 (PAK HD +/- CHD), subjects will be observed for a minimum duration of 1 h in the hospital after which they may go home if the post-dialysis period was uneventful.

Locations

Country Name City State
Singapore National University Hospital Investigational Medicine Unit Singapore

Sponsors (1)

Lead Sponsor Collaborator
Nextkidney S.A.

Country where clinical trial is conducted

Singapore, 

Outcome

Type Measure Description Time frame Safety issue
Primary The primary objective of this early feasibility clinical trial is to assess the (short term) clinical safety of the PAK HD sorbent treatment in a limited number of patients and treatments. The clinical safety of the PAK HD will be evaluated in terms of the following primary endpoints:
a) Absence of serious adverse events (SAE) b) Absence of critical change in patient's clinical condition and vital parameters (Blood pressure, heart rate, body temperature and respiratory rate and pulse oximetry) during treatment.
c) Absence of critical change in haematology and biochemistry immediately before the start of therapy and immediately after completion of therapy, including acid-base state, electrolytes, and ammonia.
2 weeks
Secondary The secondary objective of this study is to evaluate the efficacy of the PAK HD therapy in comparison to CHD, in terms of uremic toxin removal efficacy (urea, creatinine and phosphate). The therapy efficacy will be evaluated with the secondary endpoint:
a) PAK HD therapy provides equivalent toxin clearances for urea, phosphate and creatinine as compared to CHD
2 weeks
See also
  Status Clinical Trial Phase
Completed NCT04076488 - Feasibility of an Interactive Tablet-based Exercise Program for People With Chronical Diseases N/A
Completed NCT03289650 - Extended Release Tacrolimus vs. Twice-Daily Tacrolimus Phase 3
Completed NCT04042324 - A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients Phase 1/Phase 2
Completed NCT01242904 - Use of a Bimodal Solution for Peritoneal Dialysis Phase 2
Active, not recruiting NCT03183245 - Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis Phase 3
Completed NCT03257410 - Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients N/A
Completed NCT03627299 - Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors Phase 4
Recruiting NCT05917795 - Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates N/A
Terminated NCT03539861 - Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients N/A
Withdrawn NCT02130817 - Belatacept in Kidney Transplantation of Moderately Sensitized Patients Phase 4
Completed NCT05540457 - Evaluation of Non-Invasive Continuous vs Intermittent BloodPressure Monitors in Maintenance Dialysis (BP Dialysis) N/A
Not yet recruiting NCT04900610 - The Effect of Vitamin K2 Supplementation on Arterial Stifness and Cardiovascular Events in PEritonial DIAlysis N/A
Recruiting NCT02176434 - Pilot Feasibility Study of Combined Kidney and Hematopoietic Stem Cell Transplantation to Cure End-stage Renal Disease N/A
Active, not recruiting NCT02581449 - Effect of Omega-3 Fatty Acids on Oxidative Stress and Dyslipidemia in Pediatric Patients Undergoing Hemodialysis Phase 2
Completed NCT02134314 - C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI Phase 1/Phase 2
Completed NCT02832466 - Quantifying the Deterioration of Physical Function in Renal Patients N/A
Completed NCT02832440 - Comparison of Two Exercise Programmes in Patients Undergoing Hemodialysis N/A
Completed NCT02215655 - Increasing Autonomous Motivation in ESRD to Enhance Phosphate Binder Adherence N/A
Completed NCT02830490 - Reliability of Functional Measures in Hemodialysis Patient. N/A
Recruiting NCT01912001 - Virtual Ward for Home Dialysis N/A